Author:
Zhao Yifan,Shen Xiao,Zhu Ying,Wang Anqi,Xiong Yajie,Wang Long,Fei Yao,Wang Yan,Wang Wenjuan,Lin Fang,Liang Zhongqin
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Harbeck N, Alt U, Berger U, Krüger A, Thomssen C, Jänicke F, Höfler H, Kates RE, Schmitt M. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res. 2001;7(9):2757–64.
2. Skrzypczak M, Springwald A, Lattrich C, Häring J, Schüler S, Ortmann O, Treeck O. Expression of cysteine protease cathepsin L is increased in endometrial cancer and correlates with expression of growth regulatory genes. Cancer Investig. 2012;30(5):398–403.
3. Savagner P. Leaving the neighborhood: molecular mechanisms involved during epithelial mesenchymal transition. Bioessays. 2001;23(10):912–23.
4. Niessen K, Y F, Chang L, PA Hoodless D, McFadden AK. Slug is a direct notch target required for initiation of cardiac cushion cellularization. J Cell Biol. 2008;182(2):315–25.
5. Han ML, Zhao YF, Tan CH, Xiong YJ, Wang WJ, Wu F, Fei Y, Wang L, Liang ZQ. Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells. Acta Pharmacol Sin. 2016;37(12):1606–22.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献